肺腺癌中EGFR、ALK或ROS1经典驱动基因突变与22C3-PD-L1≥50%表达的相关性
本研究回顾性分析71对肺腺癌标本,评估EGFR、ALK、ROS1驱动基因突变与22C3-PD-L1肿瘤比例评分(TPS)≥50%的重叠情况。结果显示PD-L1 TPS≥50%见于29.6%的肿瘤,19例具驱动基因异常肿瘤中仅1例PD-L1 TPS≥50%,两者重叠少见(p=0.0073)。
要点
- PD-L1 TPS≥50%见于29.6%的肺腺癌。
- 19例驱动基因异常肿瘤中仅1例PD-L1 TPS≥50%(p=0.0073)。
- PD-L1 TPS≥50%与吸烟状态显著相关。
核心结论
- PD-L1免疫组化可在常规肺癌标本上进行;TPS≥50%与具获批靶向治疗的驱动基因重叠少见。
- 可定义三个生物标志物分组:EGFR/ALK/ROS1突变腺癌(约20%)配对酪氨酸激酶抑制剂;PD-L1富集腺癌TPS≥50%(约30%)配对帕博利珠单抗;生物标志物阴性腺癌(约50%)配对铂类双药化疗联合或不联合贝伐珠单抗。
研究设计与样本
- 回顾性分析本机构前71对肺腺癌患者标本,采用22C3 pharmDx试剂盒行PD-L1免疫组化检测,评估基因组异常与临床病理特征共存情况。
主要发现
- PD-L1 TPS≥50%见于29.6%的肿瘤。
- 19例具EGFR突变、ALK FISH阳性或ROS1 FISH阳性的肿瘤中,18例PD-L1 TPS<50%,仅1例PD-L1 TPS≥50%(p=0.0073)。
- PD-L1 TPS≥50%的肿瘤与吸烟状态显著相关,与患者性别、种族、肿瘤分期、活检部位或活检类型/制备无关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Targeted somatic genomic analysis (EGFR, anaplastic lymphoma receptor tyrosine kinase gene [ALK], and ROS1) and programmed death ligand 1 (PD-L1) tumor proportion score (TPS) determined by immunohistochemistry (IHC) are used for selection of first-line therapies in advanced lung cancer; however, the frequency of overlap of these biomarkers in routine clinical practice is poorly reported. METHODS: We retrospectively probed the first 71 pairs of patients with lung adenocarcinoma from our institution. They were analyzed for PD-L1 by IHC using the clone 22C3 pharmDx kit (Agilent Technologies, Santa Clara, CA) and evaluated for co-occurrence of genomic aberrations and clinicopathologic characteristics. RESULTS: Surgical resection specimens, small biopsy (transbronchial or core needle) samples, and cytologic cell blocks (needle aspirates or pleural fluid) were tested. A PD-L1 TPS of at least ≥50% was seen in 29.6% of tumors. Of 19 tumors with EGFR mutations, ALK fluorescence in situ hybridization positivity, or ROS1 fluorescence in situ hybridization positivity, 18 had a PD-L1 TPS less than 50% versus only one tumor with a PD-L1 TPS of at least 50% (p = 0.0073). Tumors with a PD-L1 TPS of at least 50% were significantly associated with smoking status compared with tumors with a PD-L1 TPS less than 50% but were not associated with patient sex, ethnicity, tumor stage, biopsy site, or biopsy type/preparation. CONCLUSIONS: PD-L1 IHC can be performed on routine clinical lung cancer specimens. A TPS of at least 50% seldom overlaps with presence of driver oncogenes with approved targeted therapies. Three biomarker-specified groups of advanced lung adenocarcinomas can now be defined, each paired with a specific palliative first-line systemic therapy of proven clinical benefit: (1) EGFR/ALK/ROS1-affected adenocarcinoma paired with a matched tyrosine kinase inhibitor (∼20% of cases), (2) PD-L1-enriched adenocarcinoma (TPS ≥50%) paired with anti-PD-1 pembrolizumab (∼30% of cases), and (3) biomarker-negative (i.e., EGFR/ALK/ROS1/PD-L1-negative) adenocarcinoma paired with platinum doublet chemotherapy with or without bevacizumab (∼50% of cases).
引用
- Rangachari D, VanderLaan PA, Shea M, et al. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma. J Thorac Oncol. 2017. PMID: 28104537. doi:10.1016/j.jtho.2016.12.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。